Navigation Links
Arcion Therapeutics' Topical Gel Candidate, ARC-4558, Demonstrates Significant Pain Reduction in Phase 2b Trial for Painful Diabetic Neuropathy (PDN)
Date:7/20/2010

low or undetectable.  No serious or severe adverse events were attributable to ARC-4558 treatment and the topical formulation was well-tolerated at the site of skin application.  

"The top-line data reported today for ARC-4558 provide strong support for Arcion's fundamental approach of applying therapies topically to relieve neuropathic pain by targeting nerve signaling at the level of the skin," said James Campbell, M.D., President and CEO of Arcion. "Through this study, we identified a simple, predictive clinical test to identify non-responders to ARC-4558, which should enable us to optimize subject enrollment in future studies.  Based on our successful End of Phase 2 meeting with the FDA, we believe ARC-4558 will be the first PDN treatment indicated to treat patients who have demonstrable functional nociceptors in the skin.  The full Phase 2b results will be submitted for future peer review and we look forward to advancing the ARC-4558 program in Phase 3 studies."

Michael C. Rowbotham, M.D., Adjunct Professor of Neurology and Anesthesia and Director, UCSF Pain Clinical Research Center, commented, "Painful diabetic neuropathy is frequently a debilitating condition that severely impacts a patient's quality of life and ability to carry out normal day-to-day functions.  There are approved therapies to control the pain, but issues of tolerability and efficacy seriously limit their usefulness.  A novel mechanism-based topical treatment with a low liability of systemic side effects has promise to advance significantly the treatment of this condition and improve the quality of life for a large number of patients."

About the Phase 2b Trial

The Phase 2b study included an adaptive trial design and enrolled a total of 180 adult patients with PDN. Pati
'/>"/>

SOURCE Arcion Therapeutics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Anesiva Announces Merger With Arcion Therapeutics Will Not be Completed
2. Arcion Therapeutics Topical Pain Candidate, ARC-4558, Significantly Reduces Pain Caused by Diabetic Neuropathy
3. Elusys Therapeutics and Lonza Extend Manufacturing Agreement for Anthim, a New Anthrax Treatment in Late-Stage Development
4. Silence Therapeutics and AstraZeneca Extend siRNA Development Collaboration
5. Nile Therapeutics Completes Dosing of Phase II Study
6. Cornerstone Therapeutics Announces Management Change
7. Nonconformity of NOV002 Used in Phase 3 NSCLC Trial Sponsored by Novelos Therapeutics, Inc to NOV002 (Glutoxim(R)), Used in Phase 1/2 NSCLC and all Previous Trials
8. InteKrin Therapeutics Presented Phase 2b Clinical Data at the 2010 American Diabetes Association Annual Meeting, Demonstrating Improved Glycemic Control in Patients with Type 2 Diabetes Without Causing the Edema Seen with Pioglitazone
9. Global Melanoma Therapeutics Industry
10. Tolera Therapeutics Granted Orphan Drug Designation for Treatment of Type 1 diabetes mellitus
11. TransGenRx Protein Therapeutics Technology to Support Research Related to Protein-Based HDL Therapies at Esperion Therapeutics
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/14/2014)... AUSTIN, Texas , Jan. 14, 2014  Luminex Corporation (Nasdaq: ... report results for the fourth quarter of 2013 on Monday, ... scheduled for release after the close of trading. ... a conference call to discuss the operating highlights and financial ...
(Date:1/14/2014)... 2014 Dynamic Healthcare Services, Inc. ("DHS"), a portfolio company ... Progressive Home Medical Equipment, Inc. ("Progressive") of Clarion, ... the acquisition were not disclosed. Progressive is ... wide range of sleep, mobility, and respiratory products to customers ...
(Date:1/14/2014)... , a manufacturer of ergonomically designed laboratory equipment for ... Japan to sell and service the Hitachi ... will utilize its network of sales professionals throughout the ... offer assistance in application use, product benefits and features, options and ...
Breaking Medicine Technology:Luminex Corporation Fourth Quarter Earnings Release Scheduled for February 3, 2014 2Luminex Corporation Fourth Quarter Earnings Release Scheduled for February 3, 2014 3Dynamic Healthcare Services Completes Progressive Home Medical Equipment of Clarion, PA Investment 2Dynamic Healthcare Services Completes Progressive Home Medical Equipment of Clarion, PA Investment 3NuAire announces sales and service of Hitachi Koki centrifuges in North America 2
(Date:4/18/2014)... made a discovery that turns 160 years of neuroanatomy ... long known to be essential for the fast transmission ... not as ubiquitous as thought, according to a new ... Stem Cell Institute (HSCI) and the University,s Department of ... Jeff Lichtman, of Harvard,s Department of Molecular and Cellular ...
(Date:4/18/2014)... did it make you feel? According to psychologists, remembering ... as how sad you were or how embarrassed you ... can,t stop thinking about it. , When these ... the memories, rather than how you felt, is a ... effects of these memories, a new study suggests. , ...
(Date:4/18/2014)... Two Simon Fraser University psychologists have made a ... treatment of attention-deficit disorders. , This discovery opens ... may hinder or suppress a specific brain activity ... prevent distraction. , The Journal of Neuroscience ... discovery by John McDonald, an associate professor of ...
(Date:4/18/2014)... This news release is available in French . ... breakthrough could revolutionize surgical practice and regenerative medicine. A ... Molle et Chimie (CNRS/ESPCI Paris Tech) and Didier Letourneur ... and Paris 13), has just demonstrated that the principle ... used in vivo to repair soft-tissue organs and tissues. ...
(Date:4/17/2014)... inflammation in benign prostate tissue was associated with ... was found even in those with low prostate-specific ... in Cancer Epidemiology, Biomarkers & Prevention , ... Research. , An analysis of prostate tissue biopsies ... of the Prostate Cancer Prevention Trial (PCPT) found ...
Breaking Medicine News(10 mins):Health News:Finding turns neuroanatomy on its head 2Health News:Finding turns neuroanatomy on its head 3Health News:New study suggests a better way to deal with bad memories 2Health News:New study suggests a better way to deal with bad memories 3Health News:Scientists discover brain's anti-distraction system 2Health News:Innovative strategy to facilitate organ repair 2Health News:Innovative strategy to facilitate organ repair 3Health News:Chronic inflammation may be linked to aggressive prostate cancer 2Health News:Chronic inflammation may be linked to aggressive prostate cancer 3
... , , NEW YORK, Sept. 16 ... Trustees, today announced the appointment of Alan Kadish, M.D., as senior ... , PHOTO: http://www.flickr.com/photos/tourocollege/3923514965/ ... institution in the United States. The college was founded by ...
... , SEBASTOPOL, Calif., Sept. 16 As ... yerba mate is quickly catching on as the newest organic ... , (Photo: http://www.newscom.com/cgi-bin/prnh/20090916/NE76510 ) , , ... the yerba mate beverage category, is driving yerba mate into the mainstream ...
... YONKERS, N.Y., Sept. 16 Welcome to ... Consumer Reports and ConsumerReportsHealth.org cover issues pertaining ... (including natural medicines), mental health, diet and nutrition, food safety, ... products, rates the effectiveness and affordability of prescription drugs, and ...
... HONG KONG, Sept. 16 /PRNewswire-Asia/ -- ... on September 10, reporters were informed that the,First World ... Endoscopy Physicians) and the First World Endoscopy Technology Expo,will ... , Professor Zhang Yangde, the ...
... used to alleviate the shortage of available liver donors. Accurate ... donor and recipient is crucial. Scholars of different countries established ... the most accurate for Chinese adults has remained unclear. ... published on August 28, 2009 in the World Journal ...
... gastrointestinal bleeding accounts for approximately 20% of emergency ... has been used as a first-line treatment option ... be used as a safe diagnostic and treatment ... refractory to endoscopic treatment. The incidence of rebleeding ...
Cached Medicine News:Health News:Touro Appoints Alan Kadish, M.D., Senior Provost and Chief Operating Officer 2Health News:Touro Appoints Alan Kadish, M.D., Senior Provost and Chief Operating Officer 3Health News:Touro Appoints Alan Kadish, M.D., Senior Provost and Chief Operating Officer 4Health News:Guayaki Delivers Powerful Rainforest Experience with Newest Yerba Mate Beverage Innovations 2Health News:Guayaki Delivers Powerful Rainforest Experience with Newest Yerba Mate Beverage Innovations 3Health News:Consumer Reports Health News 2Health News:Consumer Reports Health News 3Health News:Consumer Reports Health News 4Health News:Consumer Reports Health News 5Health News:Consumer Reports Health News 6Health News:The First World Conference of Endoscopy Physicians will be Held December 18-20, 2009, in Hong Kong 2Health News:The First World Conference of Endoscopy Physicians will be Held December 18-20, 2009, in Hong Kong 3
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
Medicine Products: